Search alternatives:
linear decrease » linear increase (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
teer decrease » greater decrease (Expand Search)
mean decrease » a decrease (Expand Search)
a large » _ large (Expand Search)
Showing 13,981 - 14,000 results of 60,026 for search '(( a ((((teer decrease) OR (mean decrease))) OR (linear decrease)) ) OR ( a large decrease ))', query time: 0.91s Refine Results
  1. 13981
    Subgroup analysis.

    Subgroup analysis. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  2. 13982
    Study outcomes.

    Study outcomes. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  3. 13983
    Effect of let-7a on expression of E2F2 and CCND2.

    Effect of let-7a on expression of E2F2 and CCND2. by Qingchuan Dong (250327)

    Published 2010
    “…After transfected with let-7a, the expression levels of E2F2, CCND2, and k-ras decreased dramatically in PC3-let-7a-GFP cells compared with that in PC3-GFP cells. β-actin was used the loading control.…”
    Save to List
    Saved in:
  4. 13984
    <i>NAB3</i> reduces the level of <i>IMD2</i> CUT terminator readthrough product from a reporter and native <i>IMD2</i> CUT and readthrough RNA, but <i>NAB3</i> does not significantly affect the termination of native <i>IMD2</i> CUT in <i>air1/2</i> cells.

    <i>NAB3</i> reduces the level of <i>IMD2</i> CUT terminator readthrough product from a reporter and native <i>IMD2</i> CUT and readthrough RNA, but <i>NAB3</i> does not significant... by Milo B. Fasken (659389)

    Published 2015
    “…<i>nab3-R331A</i>, <i>nab3-F333A</i>, and <i>nab3-S399A</i> RRM mutants do not decrease level of GFP from pREF-GFP reporter in <i>air1/2</i> cells. …”
    Save to List
    Saved in:
  5. 13985
    Dimethyl Sulfoxide Perturbs Cell Cycle Progression and Spindle Organization in Porcine Meiotic Oocytes

    Dimethyl Sulfoxide Perturbs Cell Cycle Progression and Spindle Organization in Porcine Meiotic Oocytes by Xuan Li (137217)

    Published 2016
    “…Interestingly, we did not observe the formation of the large first polar body and symmetric division for porcine oocytes treated with DMSO, contrary to findings reported in mice. 3% DMSO treatment could inhibit cumulus expansion, increase nuclear abnormality, disturb spindle organization, decrease reactive oxygen species level, and elevate mitochondrial membrane potential of porcine oocytes. …”
    Save to List
    Saved in:
  6. 13986
    Rhinorrhea-free days up to day 10.

    Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  7. 13987
    Vomit-free days up to day 10.

    Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  8. 13988
    Symptoms free-days up to day 10.

    Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  9. 13989
    Respiratory symptoms-free days up to day 10.

    Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  10. 13990
    Other symptoms-free days up to day 10.

    Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  11. 13991
    Diarrhea-free days up to day 10.

    Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  12. 13992
    Gastrointestinal symptoms-free days up to day 10.

    Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  13. 13993
    Nausea-free days up to day 10.

    Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  14. 13994
    Flow of patients in Halos trial.

    Flow of patients in Halos trial. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  15. 13995
    Cough-free days up to day 10.

    Cough-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  16. 13996
    Dyspnea-free days up to day 10.

    Dyspnea-free days up to day 10. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”
    Save to List
    Saved in:
  17. 13997
    Thymol and its combination with classical anthelmintics.

    Thymol and its combination with classical anthelmintics. by Guillermina Hernando (553795)

    Published 2019
    Save to List
    Saved in:
  18. 13998
    Pilocarpine-induced morphological changes.

    Pilocarpine-induced morphological changes. by Sean P. Flynn (765557)

    Published 2015
    Save to List
    Saved in:
  19. 13999
    Cumulative and ruptured oocysts.

    Cumulative and ruptured oocysts. by Lauren M. Childs (593877)

    Published 2017
    Save to List
    Saved in:
  20. 14000
    Average cost per household based on the number of households visited per day.

    Average cost per household based on the number of households visited per day. by Rachel Mukora (10949459)

    Published 2023
    Save to List
    Saved in:

Search Tools: